Browse by Poster Presenter

Skip to main content

ASCPT 2023 Annual Meeting Main banner

Tweets by ASCPT 2023 Annual Meeting

Browse by Poster Presenter

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

L
Lagraauw, H. Maxime

qPharmetra, LLC
PII-100 - POPULATION PHARMACOKINETIC ANALYSIS OF THE SUBLINGUAL FILM FORMULATION OF DEXMEDETOMIDINE (BXCL501) IN HEALTHY VOLUNTEERS AND ADULTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER.
H. Maxime Lagraauw
Favorite
Lam, Inez

Johns Hopkins University
PT-011 - COMPUTATIONAL SYSTEMS PHARMACOLOGY OF ANTIBODY-DRUG CONJUGATES.
Inez Lam
Favorite
Larson, Thomas

Takeda Development Center Americas, Inc.
PI-055 - DOSE SELECTION FOR BRIGATINIB TO SUPPORT PEDIATRIC DEVELOPMENT.
Thomas Larson
Favorite
León, Cristhyne

Novadiscovery
LB-015 - A TRANSLATIONAL COMPUTATIONAL MODEL OF ALLERGEN CHALLENGE TO SUPPORT THE CLINICAL DEVELOPMENT OF AN INTRANASALLY ADMINISTERED BACTERIAL LYSATE IN MILD ASTHMA.
Cristhyne León
Favorite
Lee, Hyun Kyung

Seoul National University
PT-017 - CARDIOVASCULAR SAFETY OF CARFILZOMIB IN KOREA: RETROSPECTIVE COHORT STUDY USING A NATIONWIDE ADMINISTRATIVE CLAIM DATABASE.
Hyun Kyung Lee
Favorite
Lee, Jeayoon

Seoul National University
PII-079 - POPULATION PHARMACOKINETIC MODELING OF EVEROLIMUS AND INDIVIDUALIZED DOSING DEPENDING ON PROMISING COVARIATES IN LIVER TRANSPLANT RECIPIENTS.
Jeayoon Lee
Favorite
Lee, Moon Hee

Asan Medical Center
PII-067 - PHARMACOKINETIC AND PHARMACODYNAMIC MODELING ANALYSIS OF JPI-547 IN PATIENTS WITH ADVANCED SOLID TUMOR.
Moon Hee Lee
Favorite
Lee, Nora

LG Chem
PII-080 - POPULATION PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MODELING AND SIMULATION FOR TIGULIXOSTAT, A NOVEL XANTHINE OXIDASE INHIBITOR FOR THE TREATMENT OF GOUT WITH HYPERURICEMIA.
Nora Lee
Favorite
Le, Tien

University of North Carolina at Chapel Hill
PI-028 - EVALUATING THE IMPACT OF PROTON PUMP INHIBITOR USE ON CARDIOVASCULAR OUTCOMES IN PATIENTS RECEIVING CYP2C19 GENOTYPE GUIDED ANTIPLATELET THERAPY IN A REAL-WORLD SETTING.
Tien Le
Favorite
PWIII-005 - EVALUATING THE IMPACT OF PROTON PUMP INHIBITOR USE ON CARDIOVASCULAR OUTCOMES IN PATIENTS RECEIVING CYP2C19 GENOTYPE GUIDED ANTIPLATELET THERAPY IN A REAL-WORLD SETTING.
Tien Le
Favorite
Liang, Min

Moderna Therapeutics, Inc.
PI-082 - PLASMA METHYLMALONIC ACID CONCENTRATION IS POSITIVELY ASSOCIATED WITH METABOLIC DECOMPENSATION EVENTS IN PATIENTS WITH METHYLMALONIC ACIDEMIA.
Min Liang
Favorite
PII-106 - PLASMA 3-HYDROXYPROPIONIC ACID CONCENTRATION IS POSITIVELY ASSOCIATED WITH METABOLIC DECOMPENSATION EVENTS IN PATIENTS WITH PROPIONIC ACIDEMIA.
Min Liang
Favorite
Liao, Kai

Arcus Biosciences
PII-045 - USE OF A POPULATION PHARMACOKINETIC MODELLING AND SIMULATION APPROACH TO IDENTIFY FLAT DOSES OF DOMVANALIMAB IN PHASE 3 STUDIES.
Kai Liao
Favorite
Li, Dan

Merck & Co.
PII-025 - UNDERSTANDING THE PK/PD RELATIONSHIP FOR THE METALLO-BETA-LACTAMASE (MBL) INHIBITOR MK-3402 AND PRELIMINARY DOSE PROJECTION FOR PATIENTS WITH MDR GRAM-NEGATIVE INFECTIONS.
Dan Li
Favorite
Li, Jia

Takeda Development Center Americas, Inc.
PI-011 - CHARACTERIZING THE RELATIONSHIP BETWEEN CELLULAR KINETICS AND RESPONSE TO SUPPORT DOSING RECOMMENDATIONS FOR CD19-TARGETED 19(T2)28Z1XX CELL THERAPY.
Jia Li
Favorite
Li, Lang

The Ohio State University
PI-098 - THE MATERNAL AND PEDIATRIC PRECISION IN THERAPEUTICS (MPRINT) KNOWLEDGEBASE AND PORTAL.
Lang Li
Favorite
Lim, Hyeong-Seok

Asan Medical Center
PI-015 - DEVELOPMENT OF USER-FRIENDLY BAYESIAN PREDICTIVE PLATFORM FOR BLOOD BORON-10 PHARMACOKINETICS FOLLOWING INTRAVENOUS INFUSION OF [10B]L-4-BORONOPHENYLALANINE.
Hyeong-Seok Lim
Favorite
PII-090 - TRANSLATIONAL PHARMACOKINETIC-PHARMACODYNAMIC MODELING AND SIMULATION TO PREDICT EFFICACIOUS HUMAN DOSES FOR YH35324 (GI-301)
Hyeong-Seok Lim
Favorite
Lim, KyoungSoo

AstraZeneca
EP-008 - POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSIS OF TREMELIMUMAB 300 MG SINGLE DOSE COMBINED WITH DURVALUMAB 1500 MG EVERY 4 WEEKS (STRIDE) IN UNRESECTABLE HEPATOCELLULAR CARCINOMA.
KyoungSoo Lim
Favorite
Liu, Sihang

Bristol Myers Squibb
PII-061 - MODEL INFORMED DRUG DEVELOPMENT (MIDD) TO SUPPORT AN ALTERNATIVE NIVOLUMAB DOSE AND SCHEDULE FOR ADVANCED MELANOMA.
Sihang Liu
Favorite
Liu, Tao

US Food and Drug Administration
PI-086 - COMPARISON OF DISEASE CHARACTERISTICS IN ADULTS AND CHILDREN WITH TYPE 2 DIABETES MELLITUS: IMPLICATION FOR ANTIDIABETIC DRUG DEVELOPMENT IN CHILDREN.
Tao Liu
Favorite
Lo, Arthur

Global Blood Therapeutics
PII-062 - MODEL-BASED APPROACH TO SELECT THE DOSE REGIMEN OF GBT021601, A NEXT-GENERATION SICKLE HEMOGLOBIN POLYMERIZATION INHIBITOR, IN HEALTHY VOLUNTEERS AND PATIENTS WITH SICKLE CELL DISEASE.
Arthur Lo
Favorite
PWII-001 - MODEL-BASED APPROACH TO SELECT THE DOSE REGIMEN OF GBT021601, A NEXT-GENERATION SICKLE HEMOGLOBIN POLYMERIZATION INHIBITOR, IN HEALTHY VOLUNTEERS AND PATIENTS WITH SICKLE CELL DISEASE.
Arthur Lo
Favorite